Profiling extracellular vesicles (EV) in patients with acute GvHD after allogeneic stem cell transplantation (2020) Böttcher M, Stoll A, Böttcher-Loschinski R, Rösler W, Winkler J, Mackensen A, Mougiakakos D, et al. Conference contribution Fever of unknown origin following allogeneic stem cell transplantation - an unusual case (2020) Meintker L, Kremer A, Brandt A, Spoerl S, Slanikova A, Mackensen A, Winkler J, Rösler W Conference contribution CD19 CAR-T cell treatment of CNS relapse of Burkitt's lymphoma: A case report (2020) Aigner M, Jacobs B, Gary R, Kretschmann S, Achenbach S, Mackensen A, Mougiakakos D, et al. Conference contribution 4-1BB/CD137 triggering on human monocytes leads to differentiation into macrophages with increased metabolic support and tumoricidal capacity (2020) Stoll A, Bruns H, Gamali S, Saul D, Mackensen A, Mougiakakos D Conference contribution Impact of Nrf2 expression in reconstituting T-cells of allogeneic hematopoietic stem cell transplanted patients (2020) Karl F, Stoll A, Gamali S, Böttcher-Loschinski R, Böttcher M, Baur R, Jacobs B, et al. Conference contribution A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast) (2020) Ahrens M, Escudier B, Boleti E, Grimm MO, Goupir MG, Barthelemy P, Gravis G, et al. Conference contribution Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG) (2020) Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, et al. Conference contribution Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev (2020) De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. Conference contribution Germline (G)BRCA1/2 Mutations (M) and Hematological Toxicities in Patients (PTS) with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NACT) (2020) Furlanetto J, Moebus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Luebbe K, et al. Conference contribution A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze) (2020) Loibl S, Jackisch C, Seiler S, Rastogi P, Huober L, Denkert C, Schneeweiss A, et al. Conference contribution